



Prothena Corporation plc
Investor Relations Department
331 Oyster Point Blvd
South San Francisco, CA 94080
United States

[Visit IR website](#)
[Sign-up for Email alerts](#)

NASDAQ: PRTA

Last Trade:	58.73
Trade Time:	4:00 PM ET Jun 23, 2017
Change:	1.74 (+3.053%)
Day Range	55.64 - 59.00
52-Week Range	33.53 - 68.18
Volume	604,757

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Prothena Corporation plc (Nasdaq: PRTA) is a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies for the potential treatment of diseases that involve amyloid or cell adhesion. Our antibody-based product candidates target a number of potential indications including AL amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), inflammatory diseases including psoriasis and psoriatic arthritis (PRX003), and ATTR amyloidosis (PRX004).

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

Jun 12, 2017

[Prothena Announces Appointment of Wagner Zago, PhD as Chief Scientific Officer](#)

May 16, 2017

[Prothena Announces Appointment of Sarah Noonberg, MD, PhD as Chief Medical Officer](#)

May 9, 2017

[Prothena Reports First Quarter 2017 Financial Results and Provides R&D Update](#)

May 2, 2017

[Prothena to Report First Quarter 2017 Financial Results on May 9](#)

Apr 26, 2017

[Prothena to Participate in the Deutsche Bank 42nd Annual Health Care Conference](#)

Financials [\[View all \]](#)

[First Quarter Financial Results](#)

Feb 27, 2017

[Annual Report \(10-K\)](#)

Mar 31, 2017

[Proxy Statement \(DEF 14A\)](#)

May 9, 2017

[Quarterly Report \(10-Q\)](#)

Nov 2, 2016

[Quarterly Report \(10-Q\)](#)

Aug 2, 2016

[Quarterly Report \(10-Q\)](#)